ESC 365 - REMAIN-1: A phase 3 study of recaticimab monotherapy in dyslipidaemia

ESC Professional Premium Access

REMAIN-1: A phase 3 study of recaticimab monotherapy in dyslipidaemia

Session: Late-breaking science on pharmacology

Topic: Lipid-Lowering Agents

Speaker: Professor J. Ge (Shanghai, CN)

Event: ESC Congress 2023

Congress Presentation

About the speaker

Professor Junbo Ge

Fudan University, Shanghai (China)

3 presentations

0 follower

3 more presentations in this session

ORION-8: Long-term efficacy and safety of twice-yearly inclisiran in high cardiovascular risk patients

Speaker: Professor R. Wright (Rochester, US)

Muvalaplin, a Potent Small Molecule Inhibitor of Lipoprotein(a)

Speaker: Professor S. Nicholls (Melbourne, AU)

LIBerate-HeFH - a novel PCSK9-inhibitor in heterozygous FH

Speaker: Professor F. Raal (Johannesburg, ZA)

Access the full session

Late-breaking science on pharmacology

Speakers: Professor J. Ge, Professor R. Wright, Professor S. Nicholls, Professor F. Raal

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by